Top

Published in:

Open Access 01-12-2015 | Letter to the Editor

CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder

Authors: Fengyun Dong, Chuanfeng Lu, Xiaocui Chen, Yuan Guo, Ju Liu

Published in: Diagnostic Pathology | Issue 1/2015

Abstract

Gallbladder cancer is the most common biliary tract malignancy with the worst overall prognosis. CD109 is a co-receptor of TGF-β1 and suppresses TGF-β signaling. In this study, CD109 protein expression in three subtypes of gallbladder cancer was examined by immunohistochemistry on human tissue samples and tissue microarrays. We found that CD109 is specifically expressed in malignant squamous cells in squamous cell carcinomas (86.7 %) and adenosquamous carcinomas (91.7 %), but not in adenocarcinomas or normal gallbladder tissues. Thus, CD109 may be a potential pathology marker for gallbladder squamous cell/adenosquamous carcinomas.

Lai CH, Lau WY. Gallbladder cancer--a comprehensive review. Surgeon. 2008;6(2):101–10.PubMedCrossRef

Wernberg JA, Lucarelli DD. Gallbladder cancer. Surg Clin North Am. 2014;94(2):343–60. doi:10.1016/j.suc.2014.01.009.PubMedCrossRef

Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg. 2008;196(2):252–64. doi:10.1016/j.amjsurg.2007.11.011.PubMedCrossRef

Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, et al. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB J. 2006;20(9):1525–7. doi:10.1096/fj.05-5229fje.PubMedCrossRef

Dong F, Wang Y, Li L, Wang Y, Liu X, Liu J. CD109 expression is increased in cutaneous squamous cell carcinoma. J Dermatol. 2014;41(10):947–9. doi:10.1111/1346-8138.12620.PubMedCrossRef

Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M, et al. CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int. 2005;55(4):165–9. doi:10.1111/j.1440-1827.2005.01807.x.PubMedCrossRef

Dong F, Liu F, Yan S, Liu X, Jiang Z, Liu J. Elevated Expression of CD109 in Esophageal Squamous Cell Carcinoma. Pathology oncology research : POR. 2015. doi:10.1007/s12253-014-9894-3.

Chan KM, Yu MC, Lee WC, Jan YY, Chen MF. Adenosquamous/squamous cell carcinoma of the gallbladder. J Surg Oncol. 2007;95(2):129–34. doi:10.1002/jso.20576.PubMedCrossRef

Kim WS, Jang KT, Choi DW, Choi SH, Heo JS, You DD, et al. Clinicopathologic analysis of adenosquamous/squamous cell carcinoma of the gallbladder. J Surg Oncol. 2011;103(3):239–42. doi:10.1002/jso.21813.PubMedCrossRef

10.

Roa I, Araya JC, Villaseca M, Roa J, de Aretxabala X, Ibacache G. Gallbladder cancer in a high risk area: morphological features and spread patterns. Hepatogastroenterology. 1999;46(27):1540–6.PubMed

11.

Reis-Filho JS, Torio B, Albergaria A, Schmitt FC. p63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol. 2002;29(9):517–23.PubMedCrossRef

12.

Henderson SA, Torres-Cabala CA, Curry JL, Bassett RL, Ivan D, Prieto VG, et al. p40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies. Am J Surg Pathol. 2014;38(8):1102–10. doi:10.1097/PAS.0000000000000245.PubMed

13.

Alomari AK, Glusac EJ, McNiff JM. p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma. J Cutan Pathol. 2014;41(11):839–45. doi:10.1111/cup.12388.PubMedCrossRef

14.

Charbit A, Malaise EP, Tubiana M. Relation between the pathological nature and the growth rate of human tumors. Eur J Cancer. 1971;7(4):307–15.PubMedCrossRef

15.

Nishihara K, Nagai E, Izumi Y, Yamaguchi K, Tsuneyoshi M. Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Japanese journal of cancer research : Gann. 1994;85(4):389–99.PubMedCrossRef

16.

Taylor MA, Lee YH, Schiemann WP. Role of TGF-beta and the tumor microenvironment during mammary tumorigenesis. Gene Expr. 2011;15(3):117–32.PubMedCentralPubMedCrossRef

17.

White RA, Malkoski SP, Wang XJ. TGFbeta signaling in head and neck squamous cell carcinoma. Oncogene. 2010;29(40):5437–46. doi:10.1038/onc.2010.306.PubMedCentralPubMedCrossRef

18.

Han G, Wang XJ. Roles of TGFbeta signaling Smads in squamous cell carcinoma. Cell & bioscience. 2011;1:41. doi:10.1186/2045-3701-1-41.CrossRef

19.

Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, Finnson KW, et al. The TGF-beta co-receptor, CD109, promotes internalization and degradation of TGF-beta receptors. Biochim Biophys Acta. 2011;1813(5):742–53. doi:10.1016/j.bbamcr.2011.01.028.PubMedCrossRef

Title: CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder
Authors: Fengyun Dong
Chuanfeng Lu
Xiaocui Chen
Yuan Guo
Ju Liu
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-015-0375-0

At a glance: The STEP trials

Springer Medicine

CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats

The significance of NTR1 expression and its correlation with β-catenin and EGFR in gastric cancer

Clear cell sarcoma of the kidney with calcification and a novel chromosomal abnormality: a case report

An autopsy case of myocardial infarction due to idiopathic thrombotic thrombocytopenic purpura

Retraction Note: Expression of microRNA-497 and its prognostic significance in human breast cancer

Ciliated hepatic foregut cyst: a report of 6 cases and a review of the English literature